Innovent Biologics has received approval from the Chinese NMPA for Tabosun for the treatment of colon cancer. Tabosun is a CTLA-4 monoclonal antibody. It is the world's first CTLA-4 mAb approved for the neoadjuvant treatment of colon cancer. The NDA approval is based on the results of a randomized trial. The drug is for neoadjuvant therapy, which is given before surgery to shrink the tumor[1].